Aptevo Therapeutics Inc
APVO6.700USD
+0.690+11.48%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
5.14MMarket Cap
LossP/E TTM
More Details of Aptevo Therapeutics Inc Company
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Aptevo Therapeutics Inc Info
Ticker SymbolAPVO
Company nameAptevo Therapeutics Inc
IPO dateJul 20, 2016
CEOWhite (Marvin L)
Number of employees37
Security typeOrdinary Share
Fiscal year-endJul 20
Address2401 4th Ave Ste 1050
CitySEATTLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code98121-3460
Phone12068380500
Websitehttps://aptevotherapeutics.com/
Ticker SymbolAPVO
IPO dateJul 20, 2016
CEOWhite (Marvin L)
Company Executives of Aptevo Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Marvin L. White
Mr. Marvin L. White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.00
+1.00%
Mr. Jeffrey G. Lamothe
Mr. Jeffrey G. Lamothe
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
1.00
--
Mr. Daniel J. Abdun-Nabi, J.D.
Mr. Daniel J. Abdun-Nabi, J.D.
Independent Director
Independent Director
--
--
Mr. Grady Grant, III
Mr. Grady Grant, III
Independent Director
Independent Director
--
--
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Director
Independent Director
--
--
Ms. Barbara Lopez Kunz
Ms. Barbara Lopez Kunz
Independent Director
Independent Director
--
--
Dr. John E. Niederhuber, M.D.
Dr. John E. Niederhuber, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. So Young Kwon
Ms. So Young Kwon
Senior Vice President, General Counsel, Business Development and Corporate Affairs
Senior Vice President, General Counsel, Business Development and Corporate Affairs
--
--
Ms. Daphne L. Taylor
Ms. Daphne L. Taylor
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Marvin L. White
Mr. Marvin L. White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.00
+1.00%
Mr. Jeffrey G. Lamothe
Mr. Jeffrey G. Lamothe
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
1.00
--
Mr. Daniel J. Abdun-Nabi, J.D.
Mr. Daniel J. Abdun-Nabi, J.D.
Independent Director
Independent Director
--
--
Mr. Grady Grant, III
Mr. Grady Grant, III
Independent Director
Independent Director
--
--
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Director
Independent Director
--
--
Ms. Barbara Lopez Kunz
Ms. Barbara Lopez Kunz
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Feb 3
Updated: Tue, Feb 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
1.69%
Point72 Asset Management, L.P.
1.67%
DRW Securities, LLC
0.73%
Geode Capital Management, L.L.C.
0.52%
Virtu Americas LLC
0.21%
Other
95.18%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
1.69%
Point72 Asset Management, L.P.
1.67%
DRW Securities, LLC
0.73%
Geode Capital Management, L.L.C.
0.52%
Virtu Americas LLC
0.21%
Other
95.18%
Shareholder Types
Shareholders
Proportion
Investment Advisor
2.53%
Hedge Fund
1.68%
Investment Advisor/Hedge Fund
0.52%
Research Firm
0.22%
Individual Investor
0.08%
Bank and Trust
0.02%
Other
94.96%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
39
496.31K
0.24%
--
2025Q3
40
496.31K
0.30%
+480.71K
2025Q2
36
15.60K
0.83%
-5.67K
2025Q1
33
1.27K
8.22%
-4.72K
2024Q4
31
2.43K
4.76%
+690.00
2024Q3
27
1.73K
11.60%
-920.00
2024Q2
28
2.65K
0.92%
+2.65K
2024Q1
27
3.00
7.14%
-62.00
2023Q4
27
56.00
18.23%
-45.00
2023Q3
30
101.00
11.04%
+75.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Point72 Asset Management, L.P.
16.66K
1.67%
+16.66K
--
Sep 30, 2025
DRW Securities, LLC
7.30K
0.73%
+7.30K
--
Sep 30, 2025
Virtu Americas LLC
2.13K
0.21%
+2.13K
--
Sep 30, 2025
Grant (Grady III)
751.00
0.08%
+751.00
--
Nov 10, 2025
Focus Partners Wealth, LLC
556.00
0.06%
+556.00
--
Sep 30, 2025
Osaic Holdings, Inc.
361.00
0.04%
+180.00
+99.45%
Sep 30, 2025
UBS Switzerland AG
313.00
0.03%
+313.00
--
Sep 30, 2025
Schiketanz Capital Advisors GmbH
129.00
0.01%
+97.00
+303.13%
Jul 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Dec 26, 2025
Merger
18→1
May 22, 2025
Merger
20→1
Nov 29, 2024
Merger
37→1
Nov 29, 2024
Merger
37→1
Nov 29, 2024
Merger
37→1
Nov 29, 2024
Merger
37→1
Date
Ex-dividend Date
Type
Ratio
Dec 26, 2025
Merger
18→1
May 22, 2025
Merger
20→1
Nov 29, 2024
Merger
37→1
Nov 29, 2024
Merger
37→1
Nov 29, 2024
Merger
37→1
Nov 29, 2024
Merger
37→1
Mar 04, 2024
Merger
44→1
Mar 04, 2024
Merger
44→1
Mar 04, 2024
Merger
44→1
Mar 04, 2024
Merger
44→1
View more
